Survival outcome and prognostic model of patients with colorectal cancer on phase 1 trials
{{output}}
Background Patients with metastatic colorectal cancer (mCRC) who progress on standard therapies may be eligible for phase I trials. To better delineate the risk-benefit ratio, we assessed toxicities, clinical outcomes and prognostic factors. Methods Records of... ...
